Effect of Rebamipide on the Colonic Barrier in Interleukin-10-Deficient Mice

A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury

“…Mizoguchi et al reported that prostaglandin prevented NSAID-induced small intestinal damages in rats [19]. Moreover, Megraud et al investigated that rebamipide reinforces the distal colonic barrier on mesenteric lymph node cells [20]. These mechanisms of rebamipide might play important roles as the support to the result of our present study.…”

Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study

“…Rebamipide reinforced the distal colonic barrier and had a slight Th1 immunostimulatory effect on mesenteric lymph node cells. 18 These fi ndings suggest that the effects of rebamipide include reinforcement of the distal colonic barrier and anti-infl ammatory effects.…”

“…19 These data showed the anti-infl ammatory effects of rebamipide on colonic epithelial cells. (2) Laharie et al 18 investigated the effect of rebamipide on the colonic barrier and the immune response in colitis-prone interleukin-10-defi cient C57BL/6 mice infected with Helicobacter hepaticus. Rebamipide reinforced the distal colonic barrier and had a slight Th1 immunostimulatory effect on mesenteric lymph node cells.…”

“…12,13 Rebamipide, (2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl] propionic acid) (Otsuka Pharmaceutical, Tokyo, Japan), is a cytoprotective antiulcer agent that enhances defense of the gastric mucosa by increasing gastric mucus and stimulating the production of endogenous prostaglandins, and it has been reported to reduce gastric mucosal injury. 14, 15 Mizoguchi et al 16 found that the effect of rebamipide on indomethacininduced small-intestinal mucosal injury in rebamipide has been shown to be a free-radical scavenger, 17 and Laharie et al 18 demonstrated that it reinforces the distal colonic barrier. The anti-infl ammatory effects of rebamipide on colonic epithelial cells and trinitrobenzene sulfonic acid-induced colitis in rats are due to its inhibition of the production of superoxides and suppression of myeloperoxidase activity.…”

Bacterial-mucosal interactions in inflammatory bowel disease—an alliance gone bad

“…The lack of IBD in response to monoassociation with H. hepaticus indicates that these bacteria do not by themselves possess the appropriate antigens and adjuvants to induce an immune response that can initiate and perpetuate IBD (factor 1). However, in other studies involving Helicobacter infection and IL-10 Ϫ/Ϫ mice that led to colitis (41,60,101), mice were not kept in a germ-free environment and were thus exposed to the wide variety of potentially colitigenic microbial antigens. Enhanced permeability of the barrier induced by Helicobacter infection that allows contact of colitogenic luminal bacteria with immune cells present in the lamina propria can initiate an aberrant immune response in mice with defective immune regulation that eventually results in colitis.…”